<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293460</url>
  </required_header>
  <id_info>
    <org_study_id>I10E-1302</org_study_id>
    <nct_id>NCT02293460</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of I10E in Treatment of Patients With CIDP</brief_title>
  <acronym>PRISM</acronym>
  <official_title>An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      To assess the efficacy of I10E in improving the disability of patients with CIDP.

      Secondary objective:

      To assess the safety of I10E in patients with CIDP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">September 29, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy endpoint: Responder rate at end of study (EOS) visit</measure>
    <time_frame>24-27 weeks after first treament injection</time_frame>
    <description>Responder rate at EOS visit. Responders are defined as patients with a decrease &gt;=1 point in the adjusted INCAT score between baseline and the EOS visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder rate at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>24-27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted INCAT score</measure>
    <time_frame>24-27 weeks</time_frame>
    <description>Changes from baseline to 12 weeks and EOS visit in adjusted INCAT score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength</measure>
    <time_frame>24-27 weeks</time_frame>
    <description>Changes from baseline to 12 weeks and EOS visit in Grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rasch-built Overall Disability Scale (R-ODS)</measure>
    <time_frame>24-27 weeks</time_frame>
    <description>Changes from baseline to 12 weeks and EOS visit in Rasch-built Overall Disability Scale (R-ODS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Research Council (MRC) sum score</measure>
    <time_frame>24-27 weeks</time_frame>
    <description>Changes from baseline to 12 weeks and EOS visit in Medical Research Council (MRC) sum score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</condition>
  <arm_group>
    <arm_group_label>I10E Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I10E</intervention_name>
    <description>Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.
Duration of treatment period: 21 weeks +/- 7 days.</description>
    <arm_group_label>I10E Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient aged 18 years or more

          2. Definite or probable CIDP according to the European Federation of Neurological
             Societies (EFNS)/Peripheral Nerve Society (PNS) guidelines 2010 clinical and
             neurophysiological criteria Pure motor CIDP, provided that a diagnosis of multifocal
             motor neuropathy has been ruled out CIDP associated with monoclonal gammopathy of
             undetermined significance (MGUS), provided that anti-MAG antibodies titer is lower
             than the used technique's negativity threshold (1000 BTU for Bühlmann ELISA technique)
             Lewis-Sumner syndrome

          3. Score of at least 2 on the adjusted INCAT disability scale

          4. Patient who either :

               1. has never been previously treated with Ig (Ig-naive patient) Or

               2. was previously treated with Ig but is in clinical relapse following treatment
                  withdrawal. In the latter case, the last Ig course shall have been administered
                  no less than 3 months prior to screening

        Exclusion Criteria:

          1. History of IgA deficiency, unless the absence of anti-IgA antibodies has been
             documented

          2. History of cardiac insufficiency (New York Heart Association [NYHA] III/IV),
             uncontrolled cardiac arrhythmia, unstable ischemic heart disease, or uncontrolled
             hypertension

          3. History of venous thrombo-embolic disease, myocardial infarction or, cerebrovascular
             accident

          4. Risk factor for blood hyperviscosity such as cryoglobulinemia or haematologic
             malignancy with monoclonal gammopathy

          5. Body mass Index (BMI) ≥40 kg/m²

          6. Glomerular filtration rate &lt;80 mL/min/1.73m² measured according to the Modified Diet
             in Renal Disease (MDRD) calculation

          7. Any other ongoing disease that may cause chronic peripheral neuropathy, such as toxin
             exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic
             lupus erythematosus or other connective tissue diseases, infection with HIV, hepatitis
             B virus (HBV) or hepatitis C virus (HCV), Lyme disease, multiple myeloma,
             Waldenström's macroglobulinaemia, amyloid, and hereditary neuropathy

          8. Woman with positive results on a urine pregnancy test or breastfeeding woman or woman
             of childbearing potential without an effective contraception.

          9. Any other serious medical condition that would interfere with the clinical assessment
             of CIDP or use of I10E or prevent the patient from complying with the protocol
             requirements

         10. Increasing dosage or introduction of a corticotherapy within the last 3 months prior
             to screening, with oral or systemic corticosteroids at a dose higher than 10 mg daily
             prednisolone or equivalent. Topical corticosteroids are permitted

         11. Treatment within 12 months prior to screening with immunomodulatory or
             immunosuppressant agents (including but not limited to cyclophosphamide, cyclosporine,
             interferon-alfa, interferon-beta1a, anti-CD20, alemtuzumab, aziathioprine, etanercept,
             mycophenolate mofetil, methotrexate and haemopoetic stem cell transplantation)

         12. Plasma exchange, blood products or derivatives administered within the last 3 months
             prior to screening

         13. Administration of another investigational product within the last month prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo NOBILE-ORAZIO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Instituto Clinico Humanitas, Milano, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital général du CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital l'Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Paris - Hôpital Pitié salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de saint Etienne - Hôpital nord</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRRCS Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Clinico Humanitas</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRRCS Istituto Nazionale Neurologico Besta</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele IRCCS</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliere Universitaria di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliere Universitaria san Giovanni</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario i Politècnico La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Razi</name>
      <address>
        <city>La Manouba</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Fattouma Bourguiba</name>
      <address>
        <city>Monastir</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital habib Bourguiba</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sahloul</name>
      <address>
        <city>Sousse</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital militaire de Tunis</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University medical School Neurology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical School Neurology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag University Medical School Neurology</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul UniversityCerrahpasa Medical School Neurology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara Universitesi Egitim Ve Arastirma Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Georges</name>
      <address>
        <city>London</city>
        <zip>SW17OQT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Straffordshire</name>
      <address>
        <city>Straffordshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Morocco</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral neuropathy</keyword>
  <keyword>Disimmune disease</keyword>
  <keyword>Neurology Chronic disease</keyword>
  <keyword>Rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyradiculoneuropathy</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

